Latest Ibritumomab tiuxetan Stories
New research led by the NCIC Clinical Trials Group (CTG) at Queen’s University has proven patients with limited stage Hodgkin’s lymphoma have a better chance of long-term survival if they undergo a standard chemotherapy regimen as opposed to radiation-based treatment.
SILVER SPRING, Md., Aug. 19, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL).
SEATTLE, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial.
BURLINGTON, Mass., Aug.
SAN DIEGO, Aug. 10 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today the appointment of Christine A. White, M.D., to its board of directors. Dr. White replaces Professor Paul J.
SEATTLE, June 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
Molecular imaging is leading to more individualized and effective treatment for non-Hodgkinâ€™s lymphoma by providing a map to guide the path of therapy.
SEATTLE, Feb. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
SEATTLE, Dec. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. of St.
- totally perplexed and mixed up.